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Chimeric human papillomavirus virus-like particles (HPV cVLPs) carrying HPV16 E7 protein are potent vaccines for
inducing cell-mediated immunity (CMI) against HPV-induced tumors in animal models. We tested the hypothesis that
virion-neutralizing antibodies generated during an initial vaccination might prevent effective boosting of CMI to the cVLPs.
Mice with circulating HPV16-neutralizing antibodies, generated by direct immunization with wild-type VLPs or by passive
transfer of hyperimmune anti-HPV16 VLP mouse sera, were subsequently vaccinated with HPV16 E7-containing cVLPs. Mice
with preexisting neutralizing antibodies were not protected from HPV16 E7-positive TC-1 tumor challenge, compared to the
protection seen in mice lacking these antibodies. Antibody-coated VLPs bound very inefficiently to receptor-positive cell
lines, suggesting that one of the mechanisms of antibody interference is blocking of VLP binding to its receptor and thereby
uptake of VLPs by antigen-presenting cells. Our results suggest that repetitive vaccination with a cVLP for induction of
cellular immune responses to an incorporated antigen may be of limited effectiveness due to the presence of neutralizing
antibodies against the capsid proteins induced after the first application. This limitation could potentially be overcome by
boosting with cVLPs containing the same target antigen incorporated into other papillomavirus-type VLPs. © 2001 Academic
Press
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INTRODUCTION
Both cervical dysplasia and cervical cancer in humans
are highly associated with infection by certain high-risk
human papillomaviruses (HPV), with HPV16 being found
in 50–60% of HPV-positive biopsies (Bosch et al., 1995;
Walboomers et al., 1999). Papillomaviruses are members
of the papovavirus family of viruses and consist of a
55-nm, nonenveloped, icosahedral-shaped virion. The
7.9-kb circular, double-stranded DNA viral genome con-
tains open reading frames for early proteins that are
responsible for viral DNA replication and transcription
and cellular transformation and late proteins that make
up the virus capsid. Infectious HPV virions cannot be
isolated from naturally occurring lesions, nor can they be
propagated in vitro in cell culture or in animal systems in
large enough quantities to be used as a prophylactic
vaccine. In vitro, however, the papillomavirus L1 major
and L2 minor capsid proteins are able to self-assemble
into virus-like particles (VLPs) which are highly immuno-
genic (Kirnbauer et al., 1992, 1993). VLPs mimic HPV
virions in structure and morphology (Hagensee et al.,
1994) and in their ability to induce high titers of virus-
neutralizing antibody, even in the absence of adjuvant
(Kirnbauer et al., 1992; Christensen et al., 1994). Addition-
ally, VLPs can be modified as vaccine delivery vehicles to
carry nonviral plasmid DNA (i.e., pseudovirions) (Touze
and Coursaget, 1998) or polypeptides (i.e., chimeric
VLPs; cVLPs), which upon vaccination elicit a CTL re-
sponse against tumor cells expressing the appropriate
tumor rejection antigen (Greenstone et al., 1998; Peng et
al., 1998).
Infection with papillomaviruses is strictly species-spe-
cific, therefore the use of various animal papillomavi-
ruses has allowed researchers to study the protective
effects of papillomavirus VLP-based vaccines. Immuni-
zation of rabbits, cattle, or dogs with cottontail rabbit
papillomavirus VLPs, bovine papillomavirus (BPV) VLPs,
or canine oral papillomavirus VLPs, respectively, protects
animals against infection with the homologous animal
papillomavirus (Breitburd et al., 1995; Christensen et al.,
1996c; Kirnbauer et al., 1996; Suzich et al., 1995). Passive
transfer of serum containing antibodies generated
against VLPs to naı¨ve animals similarly protects animals
from experimental virus challenge, suggesting that the
protective effect is mediated by neutralizing antibodies
(Breitburd et al., 1995; Suzich et al., 1995).
Chimeric HPV VLPs are being developed for an anti-
HPV vaccine that has the combined potential of directing
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the immune response toward prevention of virus infec-
tion and elimination of existing HPV-infected cells (Da
Silva et al., 1999). E6 and E7 are expressed in cervical
carcinoma cells and their expression is required for
maintenance of the transformed phenotype (Von Knebel
Doeberitz et al., 1994), which makes them unique and
attractive targets for cellular immunotherapy. Chimeric
HPV16 VLPs comprising HPV16 L1 and an L2–E7 fusion
protein (HPV16 L1/L2-E7 cVLPs) have been shown to
deliver the tumor rejection antigen to the immune sys-
tem, prime E7-specific CTLs, and protect mice against
challenge with E7-transformed tumor cells (Greenstone
et al., 1998). The cVLPs also retain the ability to induce
high titers of virion neutralizing antibodies. In theory,
when used in humans, the capsid component of a chi-
meric VLP would induce a protective humoral immune
response, while the protein components would be deliv-
ered to and processed by antigen-presenting cells
(APCs) and would elicit a CTL response against HPV-
induced tumor cells.
While cVLPs are able to induce both a humoral and a
cellular immune response in naı¨ve animals, it is unclear
whether the VLPs can induce a cellular immune re-
sponse (i.e., CTLs) in the presence of neutralizing anti-
bodies against HPV. Existing antibodies could arise by
natural infection with HPV, or when an individual is first
vaccinated with wild-type (wt) HPV VLPs or cVLPs. We
hypothesized that the immunogenicity of VLP-based vac-
cines would be influenced by antibodies generated by
previous exposure to the antigen. This possibility is of
potential clinical relevance since chimeric VLP-based
vaccines designed for therapeutic use will be given to
women who have already encountered HPV and will
likely need to be administered multiple times in order to
show positive effects. In the present study, we examined
the ability of HPV16 L1/L2-E7 cVLPs to elicit a cellular
immune response in the presence of existing neutraliz-
ing antibodies generated by preimmunization with wt
VLPs. The induction of effective cellular immunity was
determined by protection from E7-expressing tumor cell
challenge and quantification of antigen-specific CD8 T
cells following immunization.
RESULTS
Generation of preexistent neutralizing antibody
conditions in mice
Mice were preimmunized with wt HPV16 L1/L2 VLPs
either once or twice in order to generate a high-titered
anti-VLP antibody response prior to HPV16 L1/L2-E7
cVLP immunization. Another group of mice received hy-
perimmune anti-VLP serum isolated from mice immu-
nized with wt VLPs by passive transfer. This was done to
exclude other possible effects of immunization with wt
VLPs, such as vaccine-induced changes in lymphokine
levels or cellular immune responses against the capsid
proteins. Another group of mice was treated with a de-
fined neutralizing monoclonal antibody, H16.V5, that rec-
ognizes a conformational epitope on HPV16 L1 VLPs
(Christensen et al., 1996a) and neutralizes infectious
HPV16 virions and pseudovirions (White et al., 1999;
Roden et al., 1997). In all groups of mice, the anti-VLP IgG
antibody titer was determined by ELISA prior to mice
being immunized with HPV16 L1/L2-E7 cVLPs (Fig. 1).
Mice that were immunized once with wt VLPs and mice
that received passive transfer of hyperimmune input se-
rum had approximately equal average titers of antibody
(25 g/ml vs 30 g/ml). Mice that were boosted with a
second dose of wt VLP had a higher average anti-VLP
concentration of antibody and mice that received the
H16.V5 antibody had an intermediate final concentration
of anti-VLP antibody relative to the other experimental
groups (Fig. 1).
To confirm that immunization with our wt VLP prepa-
ration generated neutralizing antibodies, serum samples
from the mice were tested in an in vitro pseudovirion
neutralization assay (Roden et al., 1996a). In this assay,
the HPV16 capsid proteins are used to package the
genome of BPV1 and infectivity is measured in vitro by
focal transformation of mouse fibroblasts. The ability of
antiserum from a random sample of mice immunized
once or twice with wt VLPs and from the hyperimmune
FIG. 1. Anti-HPV16 VLP IgG antibody titers in mice immunized directly
with wt VLP or given antibodies by passive immunization. 6- to 8-week-
old C57Bl/6 mice (10 animals/group) were immunized once or twice
directly with wt HPV16 L1/L2 VLPs prior to HPV16 L1/L2-E7 cVLP
immunization. Mice receiving passive antibody (hyperimmune serum or
H16.V5 monoclonal antibody) were injected ip 24 h prior to chimeric
VLP immunization. Input serum was used as the source of antibody for
mice that received hyperimmune serum. Serum samples were col-
lected 1 h prior to cVLP immunization to determine the levels of
VLP-specific IgG antibodies by ELISA. Each point represents the con-
centration of anti-VLP antibody in the serum for each mouse. Numerical
values represent the mean serum concentration for each group of
animals.
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input serum to neutralize the pseudovirion preparation
was determined (Fig. 2). No transformation foci were
detected in the absence of HPV16 pseudovirions,
whereas in the presence of pseudovirions an average of
76 foci was detected (Fig. 2). The monoclonal antibody
H16.V5 inhibited focus formation by at least 50% at a titer
of 105. Fourfold dilutions of serum from mice immunized
directly with wt VLPs or from the pooled hyperimmune
serum showed neutralization titers ranging from 640 to
2560 (Fig. 2). As expected, no neutralization of
pseudovirions was observed with the preimmune normal
mouse serum control, since there were no detectable
anti-VLP antibodies without exposure to antigen (Figs. 1
and 2). These results confirm that virus-neutralizing an-
tibodies were present and readily detectable at the time
of chimeric VLP vaccination.
Presence of neutralizing antibody blocks chimeric
VLP immunization
In the presence of the neutralizing antibodies de-
scribed above, mice were immunized with a single dose
of HPV16 L1/L2-E7 cVLPs and 10 days later were chal-
lenged with E7-expressing TC-1 tumor cells to examine
induction of E7-specific anti-tumor immunity. Because
TC-1 cells express only HPV16 E6 and E7, and not the
late capsid proteins, L1 and L2, only immunization with
chimeric E7-containing VLPs (and not wt L1L2 VLPs)
protects mice from tumor challenge (Greenstone et al.,
1998). In this study, all mice that were directly preimmu-
nized with wt VLPs once prior to cVLP immunization
developed progressively growing tumors and 9/10 mice
immunized twice with wt VLPs developed tumors (Fig. 3).
All mice that were given passive anti-VLP antibody, by
means of hyperimmune serum or the neutralizing mono-
clonal H16.V5 antibody, also developed progressively
growing tumors, similar to naı¨ve PBS-immunized mice
FIG. 3. Long-term survival of mice immunized with HPV16 L1/L2-E7
cVLPs in the presence or absence of neutralizing antiserum after TC-1
tumor challenge. C57Bl/6 mice (10 animals/group) were preimmunized
sc 1 or 2 with wt VLP, were injected ip with hyperimmune anti-VLP
serum or monoclonal H16.V5 antibody, or were left untreated. Mice
were immunized sc in the left flank with HPV16 L1/L2-E7 cVLPs and 10
days later challenged sc in right flank with TC-1 tumor cells. Tumor
occurrence and volume were assessed two times per week. Mice were
sacrificed when tumor volume reached 1500 mm3 or when tumor
broke through skin surface.
FIG. 2. Neutralization of pseudovirion infection by mouse immune
serum. HPV16 L1/L2 recombinant SFV stock was used to infect BPHE-1
cells harboring the BPV1 genome to generate infectious HPV16 L1/
L2{BPV1} pseudovirions. Pseudovirions were incubated with no serum,
control normal mouse preimmune serum (NMS), H16.V5 antibody (row
B), or fourfold dilutions, starting with 1:40, of serum collected from mice
directly immunized with wt VLPs (rows C and D) or serum used for
passive transfer (row E). The serum–pseudovirus mixtures were placed
onto monolayers of mouse C127 fibroblasts. The cells were washed
after 1 h and maintained for 3 weeks, and the monolayers were stained
for visualization of transformed foci. For rows C–E, the middle plate
represents the dilution of serum that resulted in a reduction of foci
formation by at least 50% compared to the no-serum control. One
representative from two randomly chosen mice/group tested in this
assay is shown. Control plates were done in triplicate.
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(Fig. 3). In contrast, 6/10 mice immunized with HPV16
L1/L2-E7 cVLPs were completely protected from tumor
challenge. Of the 4 mice that did develop tumors, 2 had
tumors in which the growth was inhibited, resulting in a
significant survival advantage of the whole group com-
pared to all other groups in the study (P  0.0002) (Fig.
3). Similar results were obtained in two additional sets of
experiments (Table 1). Significant protection from tumor
challenge was observed only when there were no neu-
tralizing antibodies present at the time of cVLP immuni-
zation (P  0.0001) (Table 1). Immunization with wt
L1/L2 VLPs did not protect mice from TC-1 tumor chal-
lenge, confirming previously published findings (data not
shown). H16.V5 antibody and mouse anti-VLP antibodies
were not able to bind to TC-1 tumor cells by flow cytom-
etry, excluding the possibility of any direct effects of the
anti-VLP antibodies on TC-1 tumor growth (data not
shown).
In order to evaluate CD8 class I-restricted T cell
induction in the presence of neutralizing antibodies,
mice were immunized once with wt L1/L2 VLPs prior to
immunization with HPV16 L1/L2-E7 cVLPs or with HPV16
L1/L2-E7 cVLPs alone. Splenocytes from vaccinated and
control mice were tested in an ELISPOT assay for spe-
cific IFN release upon stimulation with an H-2Db-bind-
ing E7(49–57) peptide, RAHYNIVTF (Feltkamp et al., 1993),
and for binding of E7-specific T cells to H2-Db-RA-
HYNIVTF tetramer complexes (Table 2). Specific IFN-
secreting cells were detected in HPV16 L1/L2-E7 cVLP-
immunized mice, whereas mice that had been preimmu-
nized with wt VLP had on average a 9-fold lower number
of secreting cells in response to stimulation with the E7
peptide (Table 2). Double immunofluorescent staining
and flow cytometric analysis of 5-day in vitro-stimulated
splenocytes with anti-CD8 antibody and H-2Db-RA-
HYNIVTF tetramers showed an average 1.8-fold de-
crease in tetramer-positive CD8 cells from mice that
had preexisting antibodies prior to cVLP immunization
(Table 2). Taken together, the in vivo and in vitro data
indicate that the induction of E7-specific anti-tumor cell-
mediated immune (CMI) response is severely inhibited in
the presence of virus-neutralizing antibodies.
Neutralizing antibodies block VLP binding to its
receptors
Neutralizing antibodies can have different effects on
different pathogens. In the case of nonenveloped vi-
ruses, neutralizing antibodies can inhibit virus binding to
its cellular receptor and/or inhibit virus uptake and un-
coating. In order to determine what effects neutralizing
antibodies have on the VLPs used in this study, we
analyzed both the structural integrity of antibody-coated
cVLPs and the ability of antibody-coated wt VLPs to bind
to cells that express an HPV receptor(s). HPV16 L1/L2-E7
cVLPs that had been incubated with H16.V5 antibody for
30 min at room temperature were examined by electron
microscopy. The structure of the antibody-coated VLPs
looked identical to uncoated cVLPs (Fig. 4A). The struc-
ture of the cVLPs was very similar to that of wt HPV16
L1/L2 VLPs, with a capsid size of approximately 55 nm.
The data indicate that binding of a neutralizing antibody
to the VLP does not result in the destruction of capsid
structure.
Antibody-coated VLPs were tested for binding to four
different cell lines that express a papillomavirus receptor
and have been used to characterize VLP–cellular inter-
actions (Roden et al., 1994; Mu¨ller et al., 1995; Volpers et
al., 1995; Zhou et al., 1995). The addition of the H16.V5
antibody to the VLPs completely blocked VLP binding to
TABLE 2
Analysis of E7(49–57) CTL Frequencies by ELISPOT
and H-2Db-RAHYNIVTF Tetramer Staining
Vaccine group Mouse ELISPOTa Tetramer staining (%)b
PBS 1 6 4 0.7
2 13 7 1.3
3 10 2 0.9
L1L2E7 4 240 24 2.5
5 275 8 2.7
6 431 10 4.2
L1L2/L1L2E7 7 55 7 2.1
8 18 6 1.5
9 32 17 1.6
a Shown are the numbers of spots per 106 splenocytes following
stimulation with RAHYNIVTF peptide in freshly isolated splenocytes
cultured in triplicate. Figures in bold represent positive responses.
b Percentage of H-2Db-RAHYNIVTF tetramer-positive CD8 T cells in
5-day-stimulated splenocyte cultures. Figures in bold represent posi-
tive responses.
TABLE 1
Tumor-Free Animals after Immunization with HPV16 L1/L2-E7
Chimeric VLPs in the Presence of Neutralizing Antibodiesa
Vaccine group Expt 1 Expt 2 Expt 3 P valueb
PBS 1/7 0/10 0/10 Ref.
L1L2E7 5/7 5/10 6/10 0.0001
2 L1L2
L1L2E7 2/7 ndc 1/10 0.282
1 L1L2
L1L2E7 2/7 0/10 0/10 1.0
Immune sera
L1L2E7 nd nd 0/10 1.0
H16.V5
L1L2E7 nd nd 0/10 1.0
a Neutralizing antibodies were generated in vivo by direct immuni-
zation with wt L1/L2 VLPs or were given passively by ip injection prior
to immunization with chimeric HPV16 L1/L2-E7 VLPs.
b P values determined by a two-tailed Fisher’s exact test comparing
tumor incidence in PBS-vaccinated control animals to each vaccine
group using the sum of the results of three experiments.
c nd, not determined.
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SiHa cervical cancer cells and C127 mouse fibroblasts
(Fig. 4B). Greater than 80% blocking of VLP binding to
HeLa cervical cancer cells and CV-1 monkey kidney
epithelial cells was similarly observed by the addition of
H16.V5 antibody (HeLa plus VLP mean fluorescence in-
tensity (MFI), 460; HeLa plus V5-VLP MFI, 99; HeLa
control MFI, 30; CV-1 plus VLP MFI, 125; CV-1 plus
V5-VLP MFI, 45; CV-1 control MFI, 28) (Fig. 4B). VLP
binding was also tested on the mouse immature den-
dritic cell (DC) line, JAWS II, to determine whether neu-
tralizing antibodies could block VLP binding to profes-
sional APCs. Fc Block was used to prevent nonspecific
VLP–immune complex binding to Fc receptors expressed
on DCs. In the absence of immune complex binding, V5-
VLP binding to DCs was inhibited up to 70% by the
presence of neutralizing antibodies compared to normal
VLP binding to DCs (JAWS plus VLP MFI, 318; JAWS
control MFI, 99; JAWS plus V5-VLP MFI, 162) (Fig. 4C).
These data suggest that a primary mechanism for neu-
tralizing antibody-mediated inhibition of cVLP-induced
CMI response may be inhibition of VLP binding to a
cellular receptor(s), ultimately leading to an inhibition of
particle uptake and processing by APCs.
DISCUSSION
In this study we have determined that preexisting
systemic humoral immunity against HPV VLPs severely
interferes with anti-tumor CD8 T cell induction by E7-
containing HPV cVLPs in a murine tumor model system.
The abrogation of protective responses seen after wt
VLP preimmunization or after passive transfer of serum
containing antibodies generated against wt VLPs or a
defined neutralizing monoclonal antibody indicates that
neutralizing antibodies are the primary mediators of the
inhibition. Quantification of E7-specific T cells in mice
immunized with HPV16 L1/L2-E7 VLPs in the presence or
absence of preexisting antibodies revealed significantly
reduced numbers of tumor-specific T cells elicited in
mice that had preexisting humoral immunity compared to
mice without preexisting antibodies.
There are several studies that demonstrate that one
immunization with VLPs or cVLPs is sufficient to induce
antigen-specific effector CD8 T cells. Nieland et al.
demonstrated that one immunization with HPV16 L1-P1A
cVLPs is sufficient to generate P1A-specific CTLs lead-
ing to rejection of P1A P815 tumor cells after subcuta-
neous injection (Nieland et al., 1999). One injection of
HPV16 L1-E7(1–60) cVLPs was shown to also induce E7-
specific CTLs that were able to kill E7-expressing tumor
cells (Schafer et al., 1999). There are also studies in
which two immunizations of cVLPs containing an E7
epitope or the E7 protein induced good protection
against challenge with E7 tumor cells (Peng et al., 1998;
Greenstone et al., 1998). However, there are no studies
to date that demonstrate that a second immunization is
FIG. 4. Structural analysis and binding activity of antibody-coated
HPV VLPs. (A) HPV16 L1/L2 VLPs, HPV16 L1/L2-E7 cVLPs, and
H16.V5-coated HPV16 L1/L2-E7 cVLPs were examined by electron
microscopy for retention of 55-nm diameter structure. H16.V5 anti-
body was incubated with VLPs for 30 min prior to coating grids and
negative staining. Grids were analyzed at 40,000 magnification.
Bar, 100 nm. (B) Binding of antibody-coated VLPs to receptor-posi-
tive cell lines detected by flow cytometry. HeLa, SiHa, C127, and
CV-1 cell lines were incubated with biotinylated VLPs (shaded his-
tograms), V5-coated biotinylated VLPs (solid line), or biotinylated
VLPs in the presence of 50 excess of unlabeled VLPs (dashed line)
to determine nonspecific background binding, followed by the ad-
dition of streptavidin–allophycocyanin. (C) Binding of antibody-
coated VLPs to immature dendritic cells. JAWS II cells were incu-
bated with Fc Block prior to the addition of antibody-coated VLPs. All
other binding was performed as described in (B). For each sample,
15,000 viable cells were collected after gating on forward and side
scatter and exclusion of propidium iodide. Shown are representative
results of one of three independent experiments.
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required for protection or even increases the CMI re-
sponse to VLP-based vaccines, since one immunization
can induce protection similar to that of two immuniza-
tions (Greenstone et al., 1998; De Bruijn et al., 1998;
Revaz et al., 2001).
In this study, either one or two preimmunizations with
wt VLPs resulted in the same inhibitory effect on cVLP
immunization even though the neutralizing titer was
higher in twice immunized mice. No dose-dependent
inhibition was detected because all but one mouse that
were preimmunized twice and all mice preimmunized
once with wt VLPs prior to cVLP immunization developed
progressively growing tumors. However, this study does
not address the question of whether the levels of virion
antibodies elicited by natural genital tract infection by
HPV, which is approximately 40-fold lower than after VLP
vaccination (Harro et al., 2001), would also inhibit cVLP
immunization.
The data on the inhibition of antibody-coated VLP
binding to receptor-positive cell lines, including a den-
dritic cell line, suggest that a significant mechanism by
which the antibodies inhibit CMI responses is by pre-
venting binding and uptake of the VLP by APCs in a
manner that occurs in the absence of antibody. Fc re-
ceptor (FcR)-mediated uptake of immune complexes (i.e.,
antigen–IgG complexes) by murine DCs has been re-
ported to induce DC maturation and promote efficient
MHC class I- and class II-restricted peptide presentation
(Regnault et al., 1999). Surprisingly, if any FcR-mediated
uptake of the cVLP immune complexes did occur in vivo,
those events did not lead to efficient protective CTL
induction against the E7 antigen. In the case of HPV
VLPs, antibody-coated VLPs may be targeted to less
efficient APCs such as macrophages, which express
higher levels of FcR than DCs, in addition to being shut-
tled more to the exogenous MHC class II pathway of
antigen presentation.
Consistent with the idea that VLPs might normally be
targeted to professional APCs directly after immuniza-
tion, we have recently shown the direct in vitro binding of
VLPs to APCs with high affinity (Da Silva et al., 2001). Avid
VLP binding to immature DCs induces their phenotypic
maturation and secretion of T-cell-inducing cytokines
(Rudolf et al., 2001; Lenz et al., 2001). Therefore, neutral-
izing antibodies could inhibit DC binding and activation
by VLPs, thus inhibiting uptake and presentation of the
linked antigens and priming of T cell responses in the
efficient manner that seems to normally occur. That an-
tibodies preventing virus infection can also inhibit anti-
gen presentation supports the idea that access to the
cytosol of APCs, where the contents can be processed
as endogenous antigens to activate MHC class I-depen-
dent T cells, is an important mechanism by which VLPs
deliver antigens for class I presentation. In the presence
of neutralizing antibodies, the cVLPs are most likely
destroyed by opsonization, targeted to a different pro-
cessing pathway, or targeted to a different cell type, all of
which could explain the lack of an efficient anti-tumor
response observed in this study.
Although a single cVLP immunization can induce good
protection from outgrowth of injected tumor cells in mice,
it is likely that boosting of CMI responses will be re-
quired to see therapeutic effects against existing tumors
and long-term prevention of tumor recurrence in the case
of human cervical neoplasias. Therefore a challenge for
the future will be to develop strategies to effectively
boost CMI to cVLP-based vaccines by preventing or
bypassing the effects of virion-neutralizing antibodies. A
similar problem is faced by developers of viral vectors for
gene transfer. Inhibition of gene transfer and subsequent
gene expression by virus-specific neutralizing antibodies
have been described for recombinant vaccinia virus vec-
tors, recombinant adenovirus vectors, and recombinant
adeno-associated virus vectors (Rooney et al., 1988;
Dong et al., 1996; Halbert et al., 1997). Various strategies
have been used to overcome previous immunological
exposure to these traditional viral vectors, including the
use of alternative serotypes of human adenovirus (Kass-
Eisler et al., 1996; Halbert et al., 2000) and the use of
nonhuman adenovirus vectors, such as ovine adenovi-
ruses and bovine adenoviruses (Hofmann et al., 1999;
Moffatt et al., 2000). Recently, it has been shown that
altering the route of vector administration, from systemic
immunization to mucosal immunization, can also bypass
the effect of systemic neutralizing antibodies (Belyakov
et al., 1999). Some of these strategies may prove to be
useful for overcoming natural and vaccine-induced hu-
moral immunity against HPV in repeated vaccinations
with papillomavirus cVLP-based vaccines.
Multiple studies have shown that mucosal immuniza-
tion with wt VLPs or cVLPs results in the generation of
L1-specific antibodies in mucosal secretions and also
specific T cells with cytotoxic effector function (Liu et al.,
1998; Balmelli et al., 1998; Dupuy et al., 1999; Rose et al.,
1999; Revaz et al., 2001). If the mucosa does not have
significant amounts of antibody after systemic immuni-
zation, then the mucosal route of immunization remains
naı¨ve to the virus vector and can be used for the induc-
tion of immune responses in the presence of systemic
preexisting humoral immunity. Whether mucosal immu-
nization can be performed with cVLPs to boost the im-
mune system in the presence of systemic neutralizing
antibodies is currently under investigation.
In vivo and in vitro data suggest that neutralizing an-
tibodies raised against VLPs are predominantly type spe-
cific (Christensen and Kreider, 1990; Roden et al., 1995,
1996a; White et al., 1999). Notable exceptions are some
limited cross-neutralization seen between very closely
related HPV types such as HPV16 and 33, HPV18 and 45,
and HPV6 and 11 (White et al., 1999; Roden et al., 1996b;
Christensen et al., 1996b). Multiple cVLPs, containing the
same tumor rejection antigen, could be constructed from
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the L1 and L2 proteins of different HPV types or nonhu-
man papillomaviruses. After the first immunization with
one type of cVLP, the host could be boosted with a
different cVLP, as the immune system would still be naı¨ve
to the capsid of the second VLP (Greenstone et al., 1998).
The potential effects of preexisting immunity must be
considered in anticipation of clinical trials using cVLPs to
treat existing tumors or residual disease. Since neutral-
izing antibodies prevent repeated vaccination with the
same cVLP in our mouse model, and human vaccinees
develop similar antibody titers after VLP vaccination
(Harro et al., 2001), alternative strategies to deliver tumor
rejection antigens may need to be developed. These will
likely be in the forms discussed above such as altering
the routes of immunization and altering the capsid pro-
teins used to deliver the encapsidated antigens. If stud-
ies in animal models show that these strategies will not
work for papillomavirus VLPs as they have worked for
traditional virus vectors, there is still the possibility that
chimeric VLPs can be effectively used in immunization
strategies in which the method to prime an immune
response is different from the method used to boost the
immune response. Heterologous prime/boost regimens
have been shown to induce immune responses that are
stronger than boosting with the same antigen since the
immune system is naive to each new delivery method
(Hanke et al., 1998; Chen et al., 2000; van der Burg et al.,
2001). Therefore, the use of cVLPs in heterologous
prime/boost regimens would overcome the neutralizing
antibody response and could result in a more potent
anti-tumor immune response than cVLPs alone.
MATERIALS AND METHODS
Cell lines and antibodies
Cell lines were purchased from American Type Culture
Collection (Manassas, VA) unless otherwise noted. HeLa
(ATCC CCL-2), SiHa (ATCC HTB-35), and CV-1 (ATCC
CCL-70) cell lines were cultured in Iscove’s modified
Dulbecco’s medium (Biowhittaker, Walkersville, MD) sup-
plemented with 10% fetal bovine serum, 2 mM L-glu-
tamine, 50 g/ml kanamycin, and 50 mM 2-mercapto-
ethanol. C127 clone C cells were obtained from W. Vass
(National Institutes of Health, Bethesda, MD). TC-1 tumor
cells were a gift from T. C. Wu (Johns Hopkins Medical
Institutions, Baltimore, MD). TC-1 cells are mouse lung
epithelial cells transformed by HPV16 E6/E7 plus acti-
vated c-Ha-ras (Lin et al., 1996). TC-1 cells were cultured
in RPMI medium (Biowhittaker) supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 50 g/ml kana-
mycin, 50 mM 2-mercaptoethanol, 1 mM sodium pyru-
vate, 2 mM nonessential amino acids, 0.4 mg/ml G418,
and 0.2 mg/ml hygromycin. The JAWS II cell line (ATCC
CRL-11904) was cultured in RPMI medium supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 50 g/ml
kanamycin, 50 mM 2-mercaptoethanol, 1 mM sodium
pyruvate, 2 mM nonessential amino acids, and 5 ng/ml
murine GM-CSF. All cell lines were grown at 37°C with
5% CO2. Antibodies H16.V5 (mouse IgG2b) and H16.E70
(mouse IgG2b) were a generous gift from Dr. Neil Chris-
tensen (Penn State University, Hershey, PA).
Animals
C57Bl/6 (H-2b) female mice 6–8 weeks of age were
purchased from Taconic (Germantown, NY). All mice
were approximately 12–14 weeks of age at the time of
tumor challenge. Mice were housed under specific
pathogen-free conditions.
Virus-like particles
HPV16 L1/L2 VLPs were produced in Trichoplusia ni
(Hi Five) cells by infection with HPV16 L1/L2 recombinant
baculovirus. HPV16 L1/L2-E7 cVLPs were produced by
infection of Hi Five cells with recombinant baculovirus
containing the HPV16 L1 gene and the HPV16 L2–E7
chimeric fusion gene (Greenstone et al., 1998). VLPs
were purified from cells by sucrose and CsCl gradient
centrifugation, quantitated, and examined by electron
microscopy, Western blot, and ELISA as previously de-
scribed (Mu¨ller et al., 1997; Greenstone et al., 1998).
Electron microscopy
Transmission electron microscopy was performed by
adsorbing 20 l VLP samples to carbon-coated copper
grids and staining with 2% uranyl acetate. Specimens
were examined with a Zeiss EM 900 electron micro-
scope at 75 kV. For antibody-coated VLPs, 1 g of H16.V5
antibody was incubated with 1 g HPV16 L1/L2-E7
cVLPs (1010 particles) for 30 min at room temperature
prior to coating grid.
Production of hyperimmune mouse anti-VLP
antiserum
Twenty mice were immunized subcutaneously (sc)
with 30 g HPV16 L1/L2 VLPs. Three weeks later, mice
were boosted with 15 g HPV16 L1/L2 VLPs and boosted
again 3 weeks later. Two weeks after the last immuniza-
tion, mice were anesthetized, total blood was collected
by heart puncture, and mice were sacrificed by cervical
dislocation. Blood was transferred into Microtainer se-
rum separator tubes (Becton–Dickinson, Franklin Lakes,
NJ) and centrifuged for 2 min at 15,000 g. Serum was
collected, pooled, and stored at 20°C until further use.
VLP ELISA
Purified HPV16 L1/L2 VLPs (500 ng/well) were used to
coat 96-well Maxisorp ELISA plates (Nunc, Naperville,
IL). Mice sera were added to wells at dilutions from 1:100
to 1:100,000. After washing, bound antibody was de-
tected by the addition of peroxidase-labeled goat anti-
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mouse IgG antibody (Biosource, Camarillo, CA), followed
by addition of o-phenylenediamine substrate in 0.05 M
phosphate citrate buffer (Sigma, St. Louis, MO). Concen-
tration of anti-VLP antibody in the sera was determined
by extrapolation of OD490nm values to standard curves
made by using known concentrations of H16.V5 antibody
or H16.E70 antibody in the same ELISA.
Generation of HPV16 pseudovirions
HPV16 pseudovirions were generated as previously
described (Roden et al., 1996a). Briefly, infectious virions
composed of the HPV16 L1 and L2 capsid proteins and
the BPV1 genome were generated by infection of BPHE-1
hamster cells, which contain autonomously replicating
BPV genomes, with replication-defective Semliki Forest
virus (SFV) vectors expressing HPV16 L1 and L2 genes.
BPHE-1 cells were grown in complete Dulbecco’s mini-
mal essential medium (DMEM) containing 10% FBS and
penicillin/streptomycin. L1 and L2 SFV stocks were
mixed together, activated with chymotrypsin (10 mg/ml;
Boehringer Mannheim, Indianapolis, IN), and used to
co-infect 10 plates (150 mm in diameter) each with 14
million BPHE-1 cells for 2 h at 37°C. Complete DMEM
replaced the infectious material, and cells were incu-
bated for 24 h, scraped, pelleted by centrifugation, and
kept at 80°C until used.
Neutralization assay
Individual infections by the HPV16 pseudovirions were
detected as transformed foci in a monolayer of mouse
C127 cells (Roden et al., 1996a). The stored pellets from
BPHE-1 cells that had been co-infected with recombinant
SFV that express HPV16 variant 114K L1 and L2 were
sonicated in 11 ml PBS just prior to addition of sera and
infection of C127 cells. Aliquots of the sonicated
pseudovirus solution were mixed for 1 h at 4°C with PBS
or with fourfold serial dilutions of serum starting with a
1:40 dilution to assay for inhibition of focal transforma-
tion. The neutralizing monoclonal antibody H16.V5 was
used as a positive control for the assay. The pseudovi-
rus/PBS or pseudovirus/serum combination was added
to the C127 cell monolayer for 1 h at 37°C and then
replaced with DMEM and 10% fetal bovine serum. The
cells were fed twice weekly for 14–18 days, then stained
with 2.5% methylene blue, 0.5% carbol fuchsin (w/v) in
methanol for visualization of foci. The neutralization titer
was defined as the reciprocal of the highest serum
dilution that was able to reduce the number of foci
induced by the pseudovirions in the positive control plate
by at least 50%.
Biotinylation of VLPs
VLPs were biotinylated with Sulfo-NHS-biotin (Pierce,
Rockford, IL). One milligram of HPV16 L1/L2 VLPs was
incubated with biotin at a final concentration of 0.5 g/ml
at 4°C for 30 min. Biotinylation was quenched by the
addition of serum-containing medium. Excess biotin was
removed by dialysis against two changes of 0.5 M NaCl/
PBS overnight, particles were aliquoted and stored at
80°C for future use. An ELISA and electron microscopy
analysis were performed to ensure that biotinylation did
not interfere with the display of antibody-neutralizing
epitopes and there was no disruption of capsid morphol-
ogy.
VLP binding assay and FACS analysis
VLP binding as detected by flow cytometry was per-
formed as previously described (Da Silva et al., 2001).
Briefly, HeLa, SiHa, CV-1, C127, and JAWS II cells were
detached from cell culture flasks with 200 mM EDTA for 15
min at 37°C, washed once with cell culture medium, and
then washed twice with FACS buffer (PBS/0.5% BSA/0.01%
NaN3). Cells (10
6) were incubated with 1 g of biotinylated
HPV16 L1/L2 VLPs for 1 h on ice. After extensive washing,
streptavidin–allophycocyanin (Pharmingen, San Diego, CA)
was added. Fluorescence was analyzed by flow cytometry
on a Becton–Dickinson FacsCalibur using CellQuest soft-
ware (Becton–Dickinson, San Jose, CA). For antibody block-
ing experiments, biotinylated VLPs were preincubated with
H16.V5 antibody for 1 h at 4°C at a concentration of 1
g/1010 VLPs. For detection of background VLP binding,
cells were preincubated with a 50 excess of unlabeled
VLPs prior to the addition of biotinylated VLPs. For detection
of antibody-coated VLP binding to JAWS II cells, cells were
first incubated with anti-FcRII/III antibody (clone 2.4G2, Fc
Block; Pharmingen) to block binding of immune complexes
to Fc receptors. Percentage of blocking was calculated
using the following equation: [(MFI of VLP binding)  (MFI
of V5-coated VLP binding)]/[(MFI of VLP binding)  (MFI of
VLP background binding)]  100.
ELISPOT assay
The number of peptide-specific IFN-producing cells
was measured as follows. Multiscreen HA plates (Milli-
pore, Bedford, MA) were coated with 5 g/ml anti-mouse
IFN antibody (Pharmingen) in PBS at 4°C overnight.
Plates were washed with PBS/0.5% Tween 20 and
blocked with culture medium. Freshly isolated spleno-
cytes were added at 1  106 cells per well in triplicate
followed by three twofold dilutions in medium containing
25 IU IL-2 and 10 g/ml HPV16 E7(49–57) peptide. After 24 h
incubation at 37°C and 5% CO2, plates were washed with
PBS–Tween and incubated for 2 h at room temperature
with 2.5 g/ml biotinylated anti-mouse IFN antibody
(Pharmingen). After extensive washing, 1.25 g/ml avi-
din–alkaline–phosphatase (Sigma, St. Louis, MO) was
added to the wells for 2 h. Plates were developed by the
addition of BCIP/NBT substrate (Promega, Madison, WI)
for 15 min. The reaction was stopped by the addition of
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tap water and plates were dried overnight. Individual
spots were counted with a dissecting microscope. A
positive response was defined as a greater than the
average of PBS-immunized mice  3 (SD).
Tetramer analysis
H2-Db tetramers labeled with phycoerythrin and con-
taining the HPV16 E7(49–57) peptide RAHYNIVTF were ob-
tained from the NIAID Tetramer Facility (Atlanta, GA).
Splenocytes from immunized and control mice were cul-
tured for 5 days in 24-well plates with 5 g/ml RA-
HYNIVTF peptide. CD8 T cells were enriched using
MACS cell sorting (Miltenyi Biotec, Auburn, CA) prior to
tetramer staining. One million CD8-enriched spleno-
cytes were incubated for 1 h with 20 l 1:100 diluted
tetramer and 2 g FITC-labeled anti-mouse CD8 anti-
body (Pharmingen) in PBS/0.5% BSA/2 mM EDTA. Cells
were washed four times and analyzed by flow cytometry
for the percentage of cells that stained with both CD8
and the tetramer. A positive response was defined as a
greater than the average of PBS-immunized mice  3
(SD).
Chimeric VLP immunization, antibody transfer, and
tumor protection
Mice preimmunized with HPV16 L1/L2 VLPs were in-
jected sc with 30 g VLP 3 weeks (for 1 VLP immu-
nized) or 3 and 6 weeks (for 2 VLP immunized) prior to
sc immunization with 50 g HPV16 L1/L2-E7 cVLPs.
Mice receiving passive transfer of immune sera or mono-
clonal antibody H16.V5 received 0.5 ml hyperimmune
input sera or 0.2 mg H16.V6 antibody intraperitoneally
24 h prior to cVLP immunization. HPV16 L1/L2-E7 cVLPs
used to immunize mice given H16.V5 antibody ip were
additionally coated with H16.V5 antibody directly (1 g/
1010 VLPs) 30 min prior to sc injection. One hundred
microliters of blood was collected from the tail vein of
mice prior to chimeric VLP immunization to determine
ELISA and neutralization titers. Ten days after immuniza-
tion on the day of tumor challenge, TC-1 cells were
harvested and washed twice with Hanks’ balanced salt
solution (HBSS) (Sigma). Tumor challenge was per-
formed by injecting 6  104 TC-1 cells sc suspended in
100 l HBSS. Tumor diameter was measured two times
a week along three axes, and tumor volume was calcu-
lated as (diameter 1  diameter 2  diameter 3). Mice
were sacrificed when tumor burden reached1500 mm3
or when tumors broke through the skin surface.
Statistical analysis
Survival data were subjected to Kaplan–Meier survival
analysis comparing curves with the log-rank test. Tumor
incidence data were analyzed in 2  2 contingency
tables by a two-tailed Fisher’s exact test. In both cases,
a P value  0.05 was considered statistically significant.
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